发明名称 miR-193a-3p and associated genes predict tumorigenesis and chemotherapy outcomes
摘要 The disclosure provides a correlation between the expression level of the miR-193a gene, which can be regulated by its methylation status, and both tumorigenesis of and the resistance of a cancer cell to a pyrimidine antimetabolite (5-FU) based chemotherapy. In addition to the methylation status and the expression of miR-193a, its downstream genes, such as E2F1, SRSF2, and apoptotic genes such as caspase 2, are also involved and can serve as useful markers for cancer therapy prognosis and for therapy selection.
申请公布号 US9127320(B2) 申请公布日期 2015.09.08
申请号 US201313829903 申请日期 2013.03.14
申请人 Genedia Biotech Co., Ltd. 发明人 Zhu Jingde
分类号 C12Q1/68;G01N33/574 主分类号 C12Q1/68
代理机构 Sheppard Mullin Richter & Hampton LLP 代理人 Sheppard Mullin Richter & Hampton LLP
主权项 1. A method for selecting a liver cancer patient for a therapy comprising the administration of 5-FU, the method comprising measuring, in a liver tumor sample isolated from the patient, the methylation status of one or more CpG sites associated with the miR-193a gene, wherein the methylation of the one or more CpG site decreases the expression level of the miR-193a-3p RNA, and selecting the patient for the therapy when the methylation of the one or more CpG sites is present in the tumor sample.
地址 Kunshan, Jiangsu CN